Literature DB >> 22359216

Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei.

Krishna Pillai1, Javed Akhter, Terence C Chua, David L Morris.   

Abstract

Pseudomyxoma peritonei is a disease characterised by the accumulation of mucinous ascites. Thus far, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to be effective at eradicating disease. Chemotherapy has been less effective, providing disease stabilization but not demonstrating significant treatment responses. Mucolytic is a potential class of drug that may be exploited in the chemical management of this disease. A variety of potential mucolytic agents are explored in this review providing evidence of basic biochemical evidence of its efficacy with potential translational application.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22359216     DOI: 10.1007/s10637-012-9797-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  54 in total

Review 1.  Nalpha -terminal acetylation of eukaryotic proteins.

Authors:  B Polevoda; F Sherman
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

2.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

3.  Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy.

Authors:  P H Sugarbaker; D Chang
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

4.  Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.

Authors:  Z Güner; U Schmidt; M H Dahlke; H J Schlitt; J Klempnauer; P Piso
Journal:  Int J Colorectal Dis       Date:  2004-10-16       Impact factor: 2.571

5.  High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.

Authors:  Rabindra Tirouvanziam; Carol K Conrad; Teodoro Bottiglieri; Leonore A Herzenberg; Richard B Moss; Leonard A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

6.  In vivo model of pseudomyxoma peritonei for novel candidate drug discovery.

Authors:  Terence C Chua; Javed Akther; Peng Yao; David L Morris
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

Review 7.  Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence.

Authors:  A Mukherjee; A Parvaiz; T D Cecil; B J Moran
Journal:  Eur J Gynaecol Oncol       Date:  2004       Impact factor: 0.196

8.  Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  P H Sugarbaker; K A Jablonski
Journal:  Ann Surg       Date:  1995-02       Impact factor: 12.969

9.  Mucus glycoproteins secreted by respiratory epithelial tissue from cystic fibrosis patients.

Authors:  R C Frates; T T Kaizu; J A Last
Journal:  Pediatr Res       Date:  1983-01       Impact factor: 3.756

10.  Interleukin-1beta induces MUC2 gene expression and mucin secretion via activation of PKC-MEK/ERK, and PI3K in human airway epithelial cells.

Authors:  Yong-Dae Kim; Jae-Yun Jeon; Hyun Jae Woo; Jung Cheul Lee; Jin Hong Chung; Si Youn Song; Seok-Keun Yoon; Suk-Hwan Baek
Journal:  J Korean Med Sci       Date:  2002-12       Impact factor: 2.153

View more
  3 in total

1.  Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.

Authors:  Vignesh Narasimhan; Kasmira Wilson; Maneka Britto; Satish Warrier; A Craig Lynch; Michael Michael; Jeanne Tie; Tim Akhurst; Catherine Mitchell; Robert Ramsay; Alexander Heriot
Journal:  J Gastrointest Surg       Date:  2019-05-14       Impact factor: 3.452

2.  Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei.

Authors:  Anthony R Lam; Khalil Bazzi; Sarah J Valle; David L Morris
Journal:  Case Rep Oncol       Date:  2021-03-31

Review 3.  Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; David Lawson Morris
Journal:  Orphanet J Rare Dis       Date:  2014-05-05       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.